Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
February 14, 2023 08:30 ET
|
Clearmind Medicine Inc.
Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm Tel Aviv, Israel /...
Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
February 08, 2023 08:30 ET
|
Clearmind Medicine Inc.
The conference will stream live on Tuesday, February 28, at 8:30 AM EST Tel Aviv, Israel / Vancouver, Canada, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:...
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
January 31, 2023 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
January 25, 2023 08:30 ET
|
Clearmind Medicine Inc.
Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the...
Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
January 19, 2023 09:00 ET
|
Clearmind Medicine Inc.
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel Aviv, Israel / Vancouver, Canada, Jan. ...
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023 09:00 ET
|
Clearmind Medicine Inc.
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward...
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
January 10, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
January 05, 2023 09:00 ET
|
Clearmind Medicine Inc.
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv, Israel /...
Clearmind Medicine Announces Shareholders Meeting Results
December 29, 2022 06:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022 09:00 ET
|
Clearmind Medicine Inc.
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE...